Talk:Lenalidomide

Myeloma study

In relapsed or refractory myeloma, 60% complete or partial response isn't bad. JFW | T@lk 01:50, 29 November 2007 (UTC)

Phase 3 trial study of relapsed or refractory multiple myeloma, shows progression-free survival at 12 months of 83.2% when Daratumumab is combined with lenalidomide and dexamethasone, compared to 60.1% in control group of lenalidomide and dexamethasone alone. ATharanee (talk) 22:19, 19 June 2020 (UTC)

Daily Mail

Given that NICE is still reviewing its recommendation (http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11937) I wonder why the Daily Mail would anticipate on the verdict. JFW | T@lk 01:13, 29 December 2008 (UTC)

Mechanism of Action

Is there a typo in the "Mechanism of Action" paragraph? Is the 2nd use of the term "in vitro" there correct? Should it not read "in vivo"? —Preceding unsigned comment added by 142.76.1.62 (talk) 17:03, 7 January 2010 (UTC)

Teratogenicity

Does anyone have sources about the fact that lenalidomide is not teratogenic? Documents published by Celgene (the manufacturer) say otherwise: "Preliminary results of an ongoing study show that lenalidomide is teratogenic in animals and is expected to be teratogenic in humans". PsychoWEU (talk) 16:01, 17 November 2012 (UTC)

IPs and primary sources

65.175.196.35 (talk · contribs), 173.197.107.15 (talk · contribs) and now 134.174.21.190 (talk · contribs) are repeatedly adding the same sources to the article. They are either laboratory-based primary sources or primary clinical trial studies. Despite pointing out the importance of WP:MEDRS, and my addition of content based on secondary sources, the same sources keep returning.

Guys, this is not a clinical article. It is an encyclopedia article for general use. We use different sources here - the kind of sources you would imagine encyclopedias to use. JFW | T@lk 11:43, 26 January 2014 (UTC)

Point well made. Section revised with only secondary sources. — Preceding unsigned comment added by 65.175.196.35 (talk) 13:37, 26 January 2014 (UTC)

Did NICE or anyone calculate a cost per QALY

Did UK NICE or anyone calculate a cost per QALY for any indications ? - Rod57 (talk) 13:22, 12 June 2016 (UTC)

Four lenalidomide patents expiring July 2016

US patents expiring in July 2016 : 6,281,230 ; 6,555,554 ; 7,119,106 ; 8,288,415 - Rod57 (talk) 22:22, 11 August 2016 (UTC)

Problem with structures

The stereochemistry is wrongly drawn in these structures. I don't have a program here to redraw properly. Both wedges have to be reversed so that the narrow part points towards the stereogenic carbon (IUPAC). Could someone with a good drawing program help with this? Peonor (talk) 06:35, 17 December 2018 (UTC)

User:Vaccinationist fixed it on January 5. Thanks for the report! DMacks (talk) 02:34, 14 March 2019 (UTC)

Moved from article

I have moved the following content here because it lacks context/explanation. There are also display issues with the image (misplaced atom labels). If anyone wants to use it to improve the article, here it is. -- Ed (Edgar181) 15:29, 13 August 2019 (UTC)

[[File:Lenalidomidesynthesis.svg|thumb|center|700px|Lenalidomide synthesis:<ref>{{Cite journal | doi = 10.1016/S0960-894X(99)00250-4| title = Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production| journal = Bioorganic & Medicinal Chemistry Letters| volume = 9| issue = 11| pages = 1625–30| year = 1999| last1 = Muller | first1 = G. W. | last2 = Chen | first2 = R. | last3 = Huang | first3 = S. Y. | last4 = Corral | first4 = L. G. | last5 = Wong | first5 = L. M. | last6 = Patterson | first6 = R. T. | last7 = Chen | first7 = Y. | last8 = Kaplan | first8 = G. | last9 = Stirling | first9 = D. I. | pmid=10386948}}</ref>]]